Further data on selexipag (Uptravi) to be presented at CHEST 2015 Congress

Actelion Pharmaceuticals Ltd / Further data on selexipag (Uptravi) to be presented at CHEST 2015 Congress . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

ALLSCHWIL, SWITZERLAND - 22 October 2015 - Actelion Ltd ATLN today announced that further key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag (Uptravi^®) will be shared through a poster presentation at the American College of Chest Physicians' CHEST Congress in Montréal, Canada.

The poster, titled 'Individualized dosing of selexipag based on tolerability in the GRIPHON study shows consistent efficacy and safety in patients with pulmonary arterial hypertension' will be presented by Dr Richard Channick from Massachusetts General Hospital, Boston, USA, at 13.30 on 28 October. The abstract can be found online.

###

Notes to Editor:

SELEXIPAG AT CHEST-15
Poster presentation:
Individualized dosing of selexipag based on tolerability in the GRIPHON study shows consistent efficacy and safety in patients with pulmonary arterial hypertension
R. Channick
Wednesday, October 28, 13:30 

ACTELION LTD

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,400 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.

For further information please contact:

Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
http://www.actelion.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions.  Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.